The FDA approved a Phase 2b trial of CS1, a new PAH therapy being tested for its impact on lung vessel resistance and ...
People with CTEPH and higher PAWP may see fewer gains from BPA, though safety and survival remain similar, a study shows.
People with CTEPH and higher PAWP may see fewer gains from BPA, though safety and survival remain similar, a study shows.
Scientists found altered activity of the PUM1 protein plays a key role in pulmonary hypertension development, making it a PH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback